Search bioRxiv⌕ Search

Biology subjects

Snyder, L. A.

Publications and source records attributed to Snyder, L. A..

3 recordsLinked to original sources

A novel ex vivo bovine corneal infection and clearance model for Neisseria gonorrhoeae, Staphylococcus aureus, and Pseudomonas aeruginosa.

Ocular infections caused by bacterial pathogens may damage the cornea and rapidly progress to permanent blindness. Topical application of an ophthalmic formulation is often used to treat corneal infections. The animal models used in many preclinical studies frequently involve expensive in vivo experiments that compromises the corneal epithelium to mimic real life conditions such as during contact lens wear, but these do not consider other instances where infection occurs in intact corneas such as in ophthalmia neonatorum. To develop an ex vivo model of infection, bovine eyes from human food chain waste were processed and the corneas inoculated with Neisseria gonorrhoeae strain NCCP 11945, Staphylococcus aureus strain 6571, and Pseudomonas aeruginosa strain ATCC 15442 for 1 hour, 4 hours, and 6 hours, respectively. Inoculation included intact bovine corneas and those compromised with scalpel, needle, and blot methods. Recovery of N. gonorrhoeae, S. aureus, and P. aeruginosa colonies demonstrated that infection of bovine corneas was achieved with intact and compromised corneas using this model. In addition, corneas inoculated with the bacteria were treated with a suitable antibiotic, demonstrating clearance of the bacterial infections with at least 5 log10 reduction. This model is appropriate for both establishing infection and testing the ability of antimicrobial agents to clear bacterial eye infections. The bovine ex vivo model is reliable, cost-effective, suitable for different bacteria species, and reduces the need for further animal exploitation in laboratory research. Author SummaryBacterial pathogens such as Neisseria gonorrhoeae, Staphylococcus aureus, and Pseudomonas aeruginosa infect the eyes, damage the clear transparent cornea and may eventually cause blindness. Several in vivo animal models that have been used to investigate corneal infections in preclinical studies involve compromising the integrity of the corneal epithelium, which predisposes the eye to infection and simulates conditions of corneal abrasion suggested to be seen during contact lens wear. However, corneal infection in infants during ophthalmia neonatorum occurs with intact corneal epithelium and as such may not be explained by abrasion simulating models. Also, in vivo experiments are expensive, involve invasive corneal procedures despite efforts at ethical compliance, and may be time consuming. Reliable models that are quicker, cost effective, cause less (or no) discomfort to animals, and simulate a wide range of corneal infection scenarios need to be explored. Here, we demonstrate the use of a novel ex vivo bovine eye model to establish bacterial infection of the cornea, with and without compromising the corneal epithelium, and clearance of the infection with selected antimicrobial agents. The optimisation of the ex vivo bovine corneal infection model may serve as a bridge between in vitro and in vivo models of corneal infection.

microbiology↗

The safety profile of Bald's eyesalve for the treatment of bacterial infections

The rise in antimicrobial resistance has prompted the development of alternatives, such as plant-derived compounds, to combat bacterial infections. Balds eyesalve, a remedy used in the Early Medieval period, has previously been shown to have efficacy against Staphylococcus aureus grown in an in vitro model of soft tissue infection. This remedy also had bactericidal activity against methicillin-resistant S. aureus (MRSA) in a chronic mouse wound. However, the safety profile of Balds eyesalve has not yet been demonstrated, and this is vital before testing in humans. Here, we determined the safety potential of Balds eyesalve using in vitro, ex vivo, and in vivo models representative of skin or eye infections. We also confirmed that Balds eyesalve is active against an important eye pathogen, Neisseria gonorrhoeae. Low levels of cytotoxicity were observed in eyesalve-treated cell lines representative of skin and immune cells. Results from a bovine corneal opacity and permeability test demonstrated slight irritation to the cornea that resolved within 10 minutes. The slug mucosal irritation assay revealed that a low level of mucus was secreted by slugs exposed to eyesalve, indicating mild mucosal irritation. We obtained promising results from mouse wound closure experiments; no visible signs of irritation or inflammation were observed. Our results suggest that Balds eyesalve could be tested further on human volunteers to assess safety for topical application against bacterial infections. ImportanceAlternative treatment for bacterial infections are needed to combat the ever increasing repertoire of bacteria resistant to antibiotics. A medieval plant-based remedy, Balds eyesalve, shows promise as a substitute for the treatment of these infections. For any substance to be effective in the treatment of bacterial infections in humans, it is important to consider the safety profile. This is a key consideration in order to have the necessary regulatory approval. We demonstrate the safety profile of Balds eyesalve using a variety of models, including whole-organ and whole-animal models. Our results show that Balds eyesalve is mildly toxic to cultured human cells, but potentially suitable for patch tests on healthy human volunteers to assess safety for later clinical trials. Our work has the potential to transform the management of diseases caused by bacterial infections, such as diabetic foot ulcers, through topical application of a natural product cocktail based on Balds eyesalve.

microbiology↗

Effects of exposure to sublethal concentrations of methoxyfenozide on honey bee colony activity and thermoregulation

Methoxyfenozide is an insect growth regulator (IGR) commonly used in agricultural to simultaneously control pests and preserve beneficial insect populations; however, its impact on honey bees in not fully understood. We conducted field and laboratory experiments to investigate bee health in response to field-relevant doses of this pesticide. Significant effects were observed in honey bee colony flight activity and thermoregulation after being treated with methoxyfenozide. Data collected indicated that hives fed 500 ppb methoxyfenozide treated pollen patty had: 1) a significantly reduced rate of daily hive weight loss due to forager departure at the start of the colonys daily activity; 2) the end of the colonys daily activity delayed by 17-21 minutes compared to Control; and 3) higher temperature variability during the winter. Colonies in the 125 ppb treatment group had fewer differences with the Control group, but did show a delay in the foraging end time by 30-46 minutes compared to the Control. Bee colony metrics of adult bee mass and brood surface area, and individual bee measurements of head weight, newly-emerged bee weight, and hypopharyngeal gland size were not significantly affected by the methoxyfenozide exposure levels of our experiments. An experiment conducted using the same treatment groups in the spring resulted in fewer differences among groups than did the experiments conducted in the fall. Analyses of methoxyfenozide concentrations in the treatment patty, wax, and bee bread showed that: 1) observed methoxyfenozide concentrations were about 18-60% lower than the calculated concentrations; 2) no residues were observed in wax in any treatment; and 3) methoxyfenozide was detected in stored bee bread in the 500 ppb treatment, at concentrations about 1-2.5% of the observed concentration for that treatment. These results suggest that there may be significant effects on honey bee colony behavior (and possibly health) in the field that are difficult to detect through traditional hive inspections and individual metrics.

zoology↗